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ABSTRACT
The lack of population immunity to the periodically emerging pandemic influenza strains makes influenza infection especially 
dangerous. The fragmented nature of the influenza virus genome contributes to the formation of influenza virus reassortants 
containing genomic fragments from different strains. This mechanism is the main reason for the natural influenza virus antigenic 
diversity as well as for the occurrence of influenza pandemics. Vaccination is the best measure to prevent the spread of influenza 
infection, but the efficacy of existing vaccines is not sufficient, especially for the elderly and small children. Specific immunity, 
developed after disease or immunization, poorly protects against infection by influenza viruses of another subtype. In this regard, 
there is an urgent need for a more effective universal influenza vaccine that provides a long-lasting broad cross-protective immu-
nity, and is able to protect against influenza A and B viruses of all known subtypes. The basic approaches to as well as challenges 
of creating such a vaccine are discussed in this review.
INTRODUCTION
Of all the viral respiratory diseases, influenza causes the 
most severe pathology and leads to the greatest damage 
to the population health and economy. The lack of 
population immunity to the periodically emerging new 
pandemic influenza strains makes influenza infection 
especially dangerous. It is known that the Spanish flu 
caused the death of 30 to 50 million people in 1918. 
Currently, according to the World Health Organization 
(WHO) data, each year approx. 20% of the population 
worldwide, including 5-10% of adults and 20-30% of 
children become ill with influenza during seasonal 
epidemics. Severe disease forms are recorded for 3-5 
million cases, and 250,000 to 500,000 cases are lethal 
[1-3]. Economic losses caused by influenza and other 
acute respiratory viral infections account for approx. 
77% of the total damage from all infectious diseases. 
Significant losses are related both to the direct costs of 
patients’ treatment and rehabilitation, as well as to the 
indirect losses caused by a decrease in productivity and 
a reduction in corporate profits. Influenza and acute 
respiratory viral infections account for 12-14% of the 
total number of temporary disability cases [2, 4].
Furthermore, influenza infection can cause hidden 
damage, such as serious clinical complications associated 
with the nervous and cardiovascular systems, as well as 
the exacerbation of chronic diseases (diabetes, heart 
failure, chronic obstructive pneumonia, etc.) and lead to 
delayed death, especially in children under two years old, 
the elderly and people with poor health [5].
The influenza virus belongs to the family of 
Orthomyxoviridae, which includes five genera: influenza 
A, B, C, D (Thogotovirus) and Isavirus. Genomes of 
influenza A and B viruses are structurally similar, and 
consist of eight RNA genome segments of negative 
polarity. These genome segments encode 12 proteins and 
are named according to the product translated from the 
primary open reading frame: PB1, PB2, PA, HA, NP, NA, 
M, and NS [6]. The polymerase complex PB2, PB1, and 
PA transcribes one mRNA from each genomic fragment, 
which is translated to the corresponding protein. In 
addition to M1 and NS1 proteins, two other proteins - 
M2 and NEP - are coded by the two corresponding mRNA 
genomic segments M and NS by means of splicing. For 
some strains from the alternative reading frame of the 
PB1 segment PB1-F2 protein is translated [7]. All proteins 
except NS1 and PB1-F2 are structural components of a 
virus particle. Nonstructural protein NS1 accumulates in 
the cytoplasm of infected cells and acts as an interferon 
antagonist. It is assumed that the PB1-F2 protein works 
as a proapoptotic factor that inhibits the function of 
immunocompetent cells [8].
The segmented structure of the influenza virus 
genome is an inexhaustible source of new strains that 
are the result of the reassortment process. Reassortants 
contain genomic segments from different strains of the 
same genus. Reassortment is one of the mechanisms 
that form the basis of the natural antigenic diversity of 
influenza viruses, eventually leading to periodic influenza 
pandemics. The antigenic properties of influenza 
virus are determined by the surface glycoproteins - 
hemagglutinin (HA or H) and neuraminidase (NA or N). 
The HA and NA form spikes composed by HA trimers and 
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NA tetramers on the surface of the virion. In the process 
of viral replication, the HA is cleaved (HA activation) by 
cellular proteases into two subunits - HA1 and HA2 - that 
remain connected by a disulfide bond [9]. HA ectodomain 
consists of two parts: a globular part comprising HA1 
subunit and the stem region, which is formed mainly by 
HA2, and by a small part of HA1 subunits. The globular 
part includes the receptor-binding site and five antigenic 
sites, and serves as the main target for the formation of 
antibodies. Antibodies that block virus binding to the 
cell receptor are neutralizing [10]. The HA1 subunit is 
characterized by high variability. In contrast, the stem 
of the HA that is located in close proximity to the viral 
membrane is highly conservative and characterized 
by low immunogenicity [11]. The main function of the 
HA2 subunit is to ensure the fusion of the viral and the 
endosomal membranes by means of the fusion peptide. 
According to the antigenic specificity, 18 subtypes of 
HA and 11 subtypes of NA are known to date for the 
influenza A virus [12]. The subtypes H1, H2, H5, H6, H8, 
H9, H11, H12, H13, H16, H17, and H18 belong to the first 
group (I) and the subtypes H3, H4, H7, H10, H14, and 
H15 belong to the second group (II). At the same time, 
only the subtypes Н1, Н2, and Н3 of influenza virus А 
and different antigenic variants of influenza virus B, that 
are circulating in the human population, are causing the 
pandemics and seasonal influenza epidemics. 
The specific immunity generated after the disease 
or after vaccination by one subtype of influenza A 
virus poorly protects from infection by the other virus 
subtypes. The immunity to any influenza virus A subtype 
does not protect from the infection by influenza virus B, 
and vice versa - immunization against the influenza virus 
B is not effective in regard to influenza virus A.
Vaccination is the best measure to prevent the spread 
of influenza infection. During the last 60 years, a lot of 
vaccines were developed that have certain advantages 
and shortcomings. However, none of the existing 
vaccines can solve the problem of influenza morbidity 
control. The poor efficiency of the influenza vaccines 
can be explained by the high variability of the pathogen. 
Two mechanisms enable the extremely high variability 
of the influenza virus and, therefore, its ability to escape 
from the neutralizing antibodies: 1) accumulation of the 
point mutations leading to the change in the antigenic 
structure of the surface glycoproteins (antigenic drift) 
and 2) reassortment of the genomic segments coding 
surface antigens (antigenic shift). The latter might lead 
to the emergence of new subtypes of viruses that can 
cause pandemics. 
All of the existing influenza vaccines have low 
efficiency in elderly and infants [13-16]. Furthermore, 
these vaccines can protect against the circulating virus 
only if the vaccine virus has the same antigenic properties 
as the epidemic strain. Thus, the high variability of the 
virus surface antigens – HA and NA – makes the annual 
vaccination necessary. It should be mentioned that 
seasonal vaccines that are developed according to the 
WHO recommendations are not effective in the case of 
the occurrence of a new influenza pandemic virus strain 
that is fundamentally different from all of the circulating 
strains, as it happened in 2009 when the pandemic 
virus A/California/7/2009 (H1N1pdm09) emerged. One 
more example could be the low efficiency of the H3N2 
component of the seasonal vaccine 2014 due to the 
emergence of the new antigenic variant of this virus 
subtype as a result of antigenic drift [17]. Additionally, 
there are known cases of human infection by the avian 
viruses of the H5N1, H7N9, H9N2, H6N1, H7N3, and 
H10N8 subtypes. The possibility of the avian virus 
transmission from human to human has not been proved 
yet. However, in ferrets it was shown that only several 
mutations in genes coding the PB1, PB2, and HA proteins 
could lead to the emergence of the transmitting virus 
[18-20]. Viruses of H5N1 and H7N9 subtypes are highly 
pathogenic and lead to lethality up to 50% in humans. 
The spreading of these viruses is extremely dangerous. In 
this regard, there is an urgent need for the development 
of an effective universal influenza vaccine that provides 
a long-lasting broad cross-protective immunity and is 
able to protect against the influenza A and B viruses 
of all known subtypes. Several examples of the cross-
reactive antibodies that neutralize the HA of groups I 
and II of influenza viruses A as well as the antibodies 
that react with A and B viruses are known to date [21]. 
These results indicate that the creation of the universal 
influenza vaccine is possible. 
The protective role of antibodies against the 
conservative influenza virus antigens 
The main humoral immune response during the influenza 
infection is directed against the HA surface glycoprotein 
and primarily against its most variable globular part [22]. 
The HA protein has two main functions: binding to the 
cell membrane in order to ensure the virus entry into the 
cell and the fusion of the virus and the cell membranes 
that takes place in endosomes [23]. The acidification 
of endosomes leads to the HA conformational change 
resulting in the extension of the fusion peptide and 
emergence of the previously hidden parts of the subunit 
HA2 on the surface of the HA trimer. In spite of the 
continuous HA variability the stem region, responsible 
for membrane fusion, has been conserved for decades and 
has kept its functionality. In addition to the HA2 subunit, 
the inner influenza virus proteins (polymerases, NP, M1, 
M2, and NS1) are also conservative. The most conservative 
regions of these proteins could be used for the creation 
of the universal influenza vaccine. Actually, the majority 
of antibodies directed against the conservative regions 
of the inner proteins do not have the neutralizing 
activity and do not react in vitro in the hemagglutination 
inhibition (HAI) or neutralization assays [24]. Although 
these specific antibodies do not prevent the infection of 
humans with a virus, they could slow down the infection 
process. The antibodies against the HA stem region could 
block the fusion of the viral and endosomal membranes 
[25], while the antibodies against the structural proteins 
could induce the complement dependent cell lysis and 
the antibody-dependent cell cytotoxicity (ADCC) [26]. 
The interaction of the natural killers (NK) CD16 with the 
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antibody’s Fc-region leads to the release of granzime В 
or perforin and to the elimination of the infected cells 
by apoptosis [27]. Thus, the antibodies participating in 
ADCC could induce the accelerated virus clearance from 
the cells of the respiratory tract that leads to the fast 
recovery of the influenza patients. 
The cell immunity to the influenza infection 
The cell immunity also does not prevent the infection of 
the humans with influenza virus, although it could have 
a significant influence on the virus reproduction leading 
to a less severe course of illness and decreased mortality. 
The cross-protective immune response is possible if the 
epitopes of the conservative influenza virus proteins 
that are known to be predominantly recognized by 
the T-lymphocytes (CD4+ and CD8+) are presented 
effectively [28]. As was shown in animal models, the cell 
immune response might have a protective role in case of 
homological and heterological infections [29-35]. The 
results of the adaptive transfer of T-cells from the primed 
mice to the naive recipients prove the protective function 
of the CD4+ and CD8+ cells [36]. The protective function of 
the preexisting virus specific T-cells CD4+ and CD8+ was 
also shown in humans in case of experimental [37, 38] 
and natural infection by the pandemic virus H1N1 of 2009 
[39]. T-cells CD4+ were shown to control the influenza 
infection by the production of the anti-inflammatory 
cytokines and chemokines as well as by the lysis of the 
infected cells and synergy with naive B-lymphocytes or 
CD8+ cells [27, 40, 41]. Furthermore, the CD4+ cells play an 
important role in the formation and support of memory 
cells [42]. It was shown that CD8+ T-cells determine the 
accelerated virus clearance from the body [43]. Therefore, 
the universal influenza vaccine should evoke the CD8+ 
Т-cell response [44]. In order to induce the effective 
CD8+ response, virus proteins should be synthesized in 
the infected cells with the consecutive presentation of 
the CD8+ epitopes by the class I molecules of the major 
histocompatibility complex (MHC I). The influenza virus 
NP and M1 proteins play the most important role in the 
formation of CD8+ Т-cell response in the case of influenza 
infection [45]. 
The peptide vaccination as well as the vaccination 
with the whole virion or split inactivated vaccines causes 
the antibody and CD4+ T-cell response due to the antigen 
presentation by the MHC II molecules. In contrast to 
peptides, the use of the replicating virus for vaccination 
leads to the processing and presentation of antigens by 
class I and class II MHC molecules due to the synthesis 
of the viral proteins providing both humoral and cell 
immunity. In case of the intranasal immunization, the 
mucosal immunity is induced in addition to the humoral 
and cell immunity. Therefore, inducing a full immune 
response that is close to a natural infection response is 
only possible to attain in the case of vaccination with 
live attenuated vaccines or with vectors that assure the 
synthesis of the viral proteins in cytoplasm. Moreover, 
the induction of the effective T-cell response could be 
achieved by the cross-priming mechanism using such 
adjuvant as the Toll-like receptors (TLR) ligands [46]. 
The main approaches to the creation of a universal 
vaccine
The function of all the licensed influenza vaccines  – 
inactivated (whole virion, split, or subunit) or live 
(attenuated cold adapted) – is to generate the immunity 
to the globular part of HA. Antibody titers, determined by 
HAI or by neutralization assay, are considered to be the 
main surrogate marker of vaccine efficacy. 
In contrast to the variable globular part, the HA 
stem part of influenza A (groups I and II) and B viruses 
is much more conservative. There are known several 
mechanisms of direct and indirect neutralization for 
the antibodies induced to this part of HA. One of the 
mechanisms of the direct neutralization contributes to 
the prevention of HA cleavage to HA1 and HA2 subunits. 
That is achieved by the interaction of antibodies with 
the HA part that is located in the vicinity of the cleavage 
site [47]. The second mechanism of direct neutralization 
contributes to the prevention of the HA conformational 
change that is necessary for the fusion peptide release 
and the subsequent fusion of the endosomal and viral 
membranes in order to deliver the viral genome into 
the cytosol. The antibody dependent and complement 
dependent cytotoxicity are involved in the mechanisms 
of indirect neutralization [48, 49].
Vaccination practically does not induce the 
antibodies to the HA stem region, while after the natural 
infection a small quantity of these antibodies could 
be detected [22, 50-54]. The exclusion is the pandemic 
virus H1N1pdm09: in that case, the generation of the 
cross-reactive antibodies directed to the subunit HA2 
conservative sites after the disease and vaccination was 
shown [54, 55]. 
It should be mentioned that the antibodies to the 
HA stem region could play not only the protective role 
but they could also provoke the infection. Thus, the 
interaction of the complex virus-antibody with the cell 
Fc-receptor led to the facilitation of the virus penetration 
into the cell and consequently to the intensification 
of the infection process [56]. The negative role of the 
cross-reactive neutralizing antibodies to the HA stem 
region in vivo was shown during the repeated infection 
by the antigenically heterologous influenza virus. The 
enhancement of the respiratory tract infection was 
recorded after the vaccination of animals and humans 
with the inactivated vaccine and consequent infection 
by the heterological influenza strain [57-60]. Thus 
after the double immunization of pigs by whole virion 
inactivated vaccine against H1N1 virus with adjuvant, 
the enhancement of the lung pathology was recorded in 
case of a consequent infection by H1N1pdm09 virus. As 
it was found out in the course of epitopes mapping, the 
antibodies contributing to the infection enhancement 
are directed to the HA2 region from 32 to 77 amino 
acid residues that is located in close proximity to the 
fusion peptide [61]. It should be mentioned that after 
the vaccination of pigs with the live attenuated vaccine 
(cold adapted or containing the truncated NS gene), the 
pathology enhancement in the case of infection with 
H1N1pdm09 virus was not observed [62, 63]. 
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The majority of the currently being developed 
approaches to the generation of the universal vaccine 
are targeting the conservative regions of the influenza 
virus proteins. The data on the major viral targets, 
corresponding vaccines, and their assumed mechanisms 
of action, presented by the WHO at the Vaccines Advisory 
Committee (PD-VAC) meeting – 2015, are shown in 
Table  1 [64]. The analysis of the proteins’ primary 
structure of different virus strains showed that 80% of 
the virus strains of human and avian viruses contain five 
of eleven proteins (PB2, PB1, PA, NP, and M1) with the 
homological regions from 9 to 58 amino acids long. It is 
known that the HA protein has the 9 amino acid region 
that is a part of the fusion peptide (FGAIAGFIA) and is 
identical for all the influenza A viruses [65]. 
The antibodies directed to the conservative proteins 
PB2, PB1, PA, NP, and M1 do not have neutralizing activity 
but could play an important role in virus elimination by 
means of ADCC. It was shown that the NP protein could 
be temporary expressed on the surface of the cell and 
the antibodies induced by this protein could also possess 
the neutralizing activity [66]. Moreover, the NP protein 
peptides, presented on MHC class I molecules, represent 
the most important targets for the cytotoxic CD8+ cells [28].
It was discovered that the M2 protein, which forms 
the ion transmembrane channel, also has significantly 
conservative structure. The part of M2 protein, which is 
located on the surface of the virus particle and consists 
of 23 amino acids (M2e), is considered to be an attractive 
target for the construction of the universal vaccine 
[67, 68]. The antibodies directed to M2e also do not 
neutralize the virus but promote the virus elimination 
from the infected cells by the ADCC mechanism. The 
most developed preparation that is now in phase I 
clinical trials has several fragments of M2e connected to 
the hepatitis B virus core (HBc) fusion protein [69, 70].
Several examples of generating a universal vaccine are 
based on HA2 subunit. The triple immunization of mice 
with peptides representing the ectodomain НА2 (23-185 
amino acid residues) or the fusion peptide (1-38 amino acid 
residues) conjugated to the keyhole limpet hemocyanin 
(KLH)  induced the cross-reactive immunity leading to a 
decrease in the animal mortality when challenged with a 
lethal dose of heterological virus strain [71]. 
More effective protection was developed in the case of 
vaccination with chimeric HA constructs. Krammer et al. 
showed that heterosubtypic humoral immunity is induced 
in mice immunized with chimeric proteins, containing 
the HA globular parts from the viruses of different 
subtypes in combination with the HA stem region of 
the same virus [72-76]. Thus, animal immunization with 
the chimers containing the HA globular part of Н9, Н6, 
and H5 viruses and the stem region from the H1N1 virus 
(PR8/34, group I) protected the animals from the weight 
loss and mortality when challenged with the viruses of 
the I group of Н1N1, H5N1, and H6N1 subtypes, but did 
not protect them from the virus of the II group of H3N2 
subtype. Similar vaccines, containing the HA stem region 
from the virus of H3N2 subtype and the globular part 
from viruses of Н4, Н5, and Н7 subtypes, protected the 
animals that were infected with different H3N2 viruses 
as well as with H7N1 and H10N7 viruses of group II [51]. 
The study of the molecular mechanism of immunity by 
the passive transfer of the antibodies from the immune 
to naive animals showed that antibodies play the major 
role in the protection of animals. The complicated 
immunization scheme that includes the animals 
electroporation using DNA and double intramuscular 
and intranasal immunization with the protein constructs 
supplemented with the adjuvant poly (I: C) are the 
shortcomings of this approach. 
The use of the stabilized structures (mini-HA) 
generated by means of gene engineering, based on the 
amino acid sequence of the HA stem region of the H1N1 
virus, serves as an example of a different approach to the 
generation of the universal influenza vaccine. Only the 
structures with the highest affinity to the antibodies that 
have a broad range of neutralizing activity were selected 
from the large library. The immunization of mice with 
these structures also protected the animals from death 
when challenged with highly pathogenic avian influenza 
virus of H5N1 subtype (group I) [77]. The complete 
protection of mice from death was achieved by the double 
intramuscular immunization with 30 µg of the purified 
mini-HA protein supplemented with the Matrix-M 
adjuvant produced by Novavax. The protective efficacy of 
this preparation was also proved in cynomolgus monkeys 
(Macaca fascicularis). The animals that were immunized 
three times intramuscularly with 150 µg of the protein 
together with 50 µg of adjuvant Matrix-M (which is not 
licensed for humans) demonstrated a significantly lower 
body temperature than the control animals after infection 
with a sublethal dose of the A/Mexico/InDRE4487/2009 
(H1N1) virus.
Table 1. Viral targets for broadly reactive influenza vaccines (reprinted with permission of WHO)
Protein antigen Targeted function Proposed mechanism of protection
Hemagglutinin (HA) Receptor binding and membrane 
fusion
Inhibition of fusion, maturation of HA, ADCC
Ectodomain of M2 (M2e) Ion channel Complement-mediated lysis, ADCC, antibody- dependent 
NK cell activity
Neuraminidase (NA) Cleaves sialic acid releasing virus 
from the surface of infected cells
Inhibition of viral spread
Matrix 1 (M1) T cell stimulation Cell lysis by CD8+ cytotoxic T lymphocytes (CTLs), CD4+ T 
lymphocyte-mediated cytolysis and B cell stimulationNucleoprotein (NP)
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The other prospective direction in the development of 
the universal influenza vaccine is based on the design of the 
self-assembling nanoparticles that significantly enhance 
the immunogenic properties of HA [78]. The nanoparticles 
were generated based on the nucleotide sequence 
of the HA2 subunit of the А/New Caledonia/20/1999 
virus. The HA stabilized-stem immunogen lacked the 
transmembrane and cytoplasmic regions of HA2 but 
contained additional mutations that stabilize the HA2 
trimer structure. In order to ensure the self-assembling of 
nanoparticles, the subunit of the ferritin protein, isolated 
from the Helicobacter pylori, was attached to the C-end of 
the obtained HA stabilized-stem immunogen [79]. As a 
result, the spherical particles with 8 spikes on the surface 
were obtained. Their protective properties were studied in 
mouse and ferret models. The animals were immunized 2 or 
3 times intramuscularly with nanoparticles supplemented 
with the new adjuvant SAS (Sigma Adjuvant System). 
The specificity of antibodies was determined by ELISA. 
It was shown that the induced antibodies were binding 
to the influenza viruses of group  I (Н1, Н2, Н5 and Н9) 
and to a lesser extent - to the viruses of group II (Н3 
and Н7). Although there were no antibodies revealed 
by HAI test, the antibodies neutralizing the viruses 
A/California/04/2009 and A/Singapore/6/1986 of the 
H1N1 subtype were detected. The antibodies to the 
viruses of H5N1, H2N2, and H9N2 subtypes were neither 
detected in mice nor in ferrets. In spite of the lack of the 
neutralizing antibodies to the virus of the H5N1 subtype 
in mice as well as in ferrets, these animals turned out to 
be completely protected from death when infected with a 
highly pathogenic H5N1 avian virus. 
One of the modern technologies for the generation 
of live vaccine is based on the construction of the 
corresponding vaccine vector that enables to express the 
antigens of one virus by the other virus. Different DNA-
containing viruses, namely: adenovirus [80], herpesvirus 
[81], baculovirus [82], or poxvirus [83], are used as the 
vectors for the expression of influenza antigens. Thus, the 
experiments with the adenovirus vector showed that the 
triple immunization with plasmid (50 µg) containing the 
sequences of the influenza virus A conservative proteins 
NP and M2, followed by intranasal infection with the 
two adenovirus vectors that express the same proteins, 
led to the complete protection of mice and ferrets from 
death and weight loss against challenge with the virus 
A/FM/1/47 (H1N1) or with the highly pathogenic strain 
of the avian influenza virus of the H5N1 subtype [84, 85]. 
Several adenovirus vectors that express the conservative 
influenza virus antigens developed for the intranasal 
immunization in humans are known to date [86]. 
All of the discussed approaches prove the possibility 
of the generation of a vaccine that will protect from 
infection with influenza viruses of group I as well as 
group II. However, none of the preparations described 
above present a vaccine that ensures protection from 
influenza virus B. Initially, influenza viruses A and B 
were separated based on the antigenic differences in 
NP and M proteins. The sequence homology of these 
proteins between influenza viruses A and B reaches only 
36% and 27%, respectively. The sequence homology of the 
HA and NA proteins is even lower and makes up 18% and 
20%, respectively. The only HA region almost completely 
identical in both types of viruses is the fusion peptide that 
is represented by the sequence (L/I/F)FGAIAGFIE(G/N)
GW. It was shown that the antibodies generated after the 
immunization with this peptide attach to virus A (H1-
H13) HA as well as to B viruses [85]. A protective epitope 
was also discovered in the HA stem region that induces 
the antibodies reacting with both influenza A and B 
viruses. The monoclonal antibody CR9114, directed to 
this epitope, protected mice from infection with influenza 
A and B viruses [87]. In addition, the T-cell CD4+ [69] and 
CD8+ epitopes that recognize the HLA-A2.1 motif [88] 
were identified in the fusion peptide. 
CONCLUSION 
Based on the literature data analysis, it is possible to 
assume that the generation of the universal influenza 
vaccine that is capable of ensuring protection from all 
known antigenic variants of influenza A and B viruses 
is feasible. A number of such preparations are currently 
being developed. The progress of these research projects 
is under the control of the WHO. The main companies 
that are designing and developing the universal influenza 
vaccines and the principals of action of these vaccines 
are shown in the Table 2 [89]. 
Ideally, the universal influenza vaccine should 
induce the antibody and T-cell immune response to the 
conservative influenza virus epitopes. It is obvious that 
the efficacy of this vaccine would depend on the variety 
of the involved epitopes and on the Th1 polarization of 
the immune response. The analysis of the experimental 
results led the author to the conclusion that the 
generation of live intranasal vector vaccines using the 
influenza virus itself as a vector for the expression of the 
conservative antigenic determinants appears to be the 
most prospective approach in current research. These 
vaccine candidates are capable of inducing the enhanced 
Th1 systemic and the local mucosal immune response at 
the infection entry. The current research data prove that 
the vector technology based on the modification of the 
NS segment of influenza virus enables the generation 
of highly immunogenic recombinant virus strains that 
express the foreign sequences from the NS1 reading 
frame [90-96]. Clinical trials showed that viruses with 
the modified NS gene are safe and highly immunogenic 
[97]. The single immunization of mice with the vector 
strain based on the influenza virus A that express HA2 
segments of the A and B influenza viruses from the NS1 
open reading frame ensures the protection of animals 
from death not only after being challenged with influenza 
A viruses of other subtypes, but also after infection 
with the influenza virus В/Lee/40 (unpublished results). 
Therefore, the formation of the influenza vectors that 
additionally express the conservative epitopes together 
with the NS1 protein appears to be the prospective 
direction toward the generation of a universal influenza 
vaccine. 
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Table 2. Development Status of Current Vaccine Candidates (reprinted with permission of WHO)
Organization 
Identifier













Rational antigen design (HA) based on preferential presentation 
of conserved epitopes for antibody response.
X
VaxInnate (USA)
Fusion protein between influenza M2e and bacterial flagellin 










Six long peptides from four core influenza proteins conjugated to 
fluorocarbon chain, elicits strong T cell response, proposed to be 





Proposed as “universal primer” to be followed by conventional 
TIV boost to potentiate HAI responses. Consists of a mixture of 
peptides comprising nine B and T cell conserved linear epitopes 





Mixture of 4 chemically synthesized peptides targeting conserved 
T cell epitopes present in M1, NPA, NPB and M2. Proposed to be 




Fusion between M2e and hepatitis B virus core protein for virus-
like particle expression and antibody-directed response.
X
Inovio (USA)
DNA plasmids encoding consensus sequences of HA, NA, and NP 




Fusion protein comprised of two highly conserved influenza 
antigens, NP, and M2e, covalently linked to proprietary 





Synthetic peptides derived from conserved B cell epitopes from 
HA modified with MHC Class 2 for facilitated Th activity. En-




of Allergy and 
Infectious Diseases 
(USA)
Adenovirus encoding HA to prime followed by inactivated vaccine 
(TIV) boost.
X
Fusion protein between self-assembling ferritin protein and HA 





Replication-deficient modified vaccinia Ankara (MVA) virus ex-
pressing both NP and M1. Designed for strong cross-reactive T cell 
response. Self –adjuvanted.
X
Replication-deficient simian adenovirus expressing both NP and 
M1. Designed for strong cross-reactive T cell response.
X
MVA expressing NP, M1 and conserved portion of HA. X
Wistar Institute
(USA)





Whole virion gamma-irradiated virus for intranasal application. 




and Gene Therapy 
Institute (USA)
Computer optimized consensus HA sequence. Elicits broad 
antibody response. Alum adjuvanted.
X
FluGen (USA)
Single-replication influenza virus which is not attenuated but 






Rearranged genome of influenza virus permitting expression of 
two HA on the same virus, while also attenuating it.
X
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Organization 
Identifier








Icahn School of 
Medicine at Mount 
Sinai (USA)
Various approaches to target conserved broadly reactive epitopes 
on HA stalk, such as “headless” HA or functional chimeric HA 
(comprised of non-matched “head” and “stalk”) expressed either 





Synthetic mRNA encoding HA and NP. Temperature-stable 
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